Literature DB >> 32671942

Sharing the cure: Building primary care and public health infrastructure to improve the hepatitis C care continuum in Maryland.

Risha Irvin1, Boatemaa Ntiri-Reid2, Mary Kleinman2, Tracy Agee1, Jeffrey Hitt2, Onyeka Anaedozie2, Tolu Arowolo2, Hope Cassidy-Stewart2, CaSaundra Bush2, Lucy E Wilson2, Alexander J Millman3, Noele P Nelson3, Lauren Canary3, Sherilyn Brinkley1, Juhi Moon1, Oluwaseun Falade-Nwulia1, Mark S Sulkowski1, David L Thomas1, Michael T Melia1.   

Abstract

In 2014, trained healthcare provider capacity was insufficient to deliver care to an estimated 70 000 persons in Maryland with chronic hepatitis C virus (HCV) infection. The goal of Maryland Community Based Programs to Test and Cure Hepatitis C, a public health implementation project, was to improve HCV treatment access by expanding the workforce. Sharing the Cure (STC) was a package of services deployed 10/1/14-9/30/18 that included enhanced information technology and public health infrastructure, primary care provider training and practice transformation. Nine primary care sites enrolled. HCV clinical outcomes were documented among individuals who presented for care at sites and met criteria for HCV testing including risk factor or birth cohort (born between 1945 and 1965) based testing. Fifty-three providers completed the STC training. STC providers identified 3237 HCV antibody-positive patients of which 2624 (81%) were RNA+. Of those HCV RNA+, 1739 (66%) were staged, 932 (36%) were prescribed treatment, 838 (32%) started treatment, 721 (27%) completed treatment and 543 (21%) achieved cure. Among 1739 patients staged, 693 (40%) patients had a liver fibrosis assessment score < F2, rendering them ineligible for treatment under Maryland Medicaid guidelines. HCV RNA testing among HCV antibody-positive people increased from 40% (baseline) to 95% among STC providers. Of 554 patients with virologic data reported, 543 (98%) achieved cure. Primary care practices can effectively serve as HCV treatment centers to expand treatment access. However, criteria by insurance providers in Maryland were a major barrier to treatment.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatitis c; hepatitis c care continuum; provider task shifting; public health; video conference training

Mesh:

Year:  2020        PMID: 32671942      PMCID: PMC7721959          DOI: 10.1111/jvh.13360

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.517


  23 in total

1.  Outcomes of treatment for hepatitis C virus infection by primary care providers.

Authors:  Sanjeev Arora; Karla Thornton; Glen Murata; Paulina Deming; Summers Kalishman; Denise Dion; Brooke Parish; Thomas Burke; Wesley Pak; Jeffrey Dunkelberg; Martin Kistin; John Brown; Steven Jenkusky; Miriam Komaromy; Clifford Qualls
Journal:  N Engl J Med       Date:  2011-06-01       Impact factor: 91.245

2.  Changes in blood-borne infection risk among injection drug users.

Authors:  Shruti H Mehta; Jacqueline Astemborski; Gregory D Kirk; Steffanie A Strathdee; Kenrad E Nelson; David Vlahov; David L Thomas
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

3.  Barriers to Treatment Access for Chronic Hepatitis C Virus Infection: A Case Series.

Authors:  Alexander J Millman; Boatemaa Ntiri-Reid; Risha Irvin; Maggie H Kaufmann; Andrew Aronsohn; Jeffrey S Duchin; John D Scott; Claudia Vellozzi
Journal:  Top Antivir Med       Date:  2017 Jul/Aug

4.  Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.

Authors:  Sarah Kattakuzhy; Chloe Gross; Benjamin Emmanuel; Gebeyehu Teferi; Veronica Jenkins; Rachel Silk; Elizabeth Akoth; Aurielle Thomas; Charisse Ahmed; Michelle Espinosa; Angie Price; Elana Rosenthal; Lydia Tang; Eleanor Wilson; Soren Bentzen; Henry Masur; Shyam Kottilil
Journal:  Ann Intern Med       Date:  2017-08-08       Impact factor: 25.391

5.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.

Authors:  Bryce D Smith; Rebecca L Morgan; Geoff A Beckett; Yngve Falck-Ytter; Deborah Holtzman; Chong-Gee Teo; Amy Jewett; Brittney Baack; David B Rein; Nita Patel; Miriam Alter; Anthony Yartel; John W Ward
Journal:  MMWR Recomm Rep       Date:  2012-08-17

6.  Hepatitis C continuum of care and utilization of healthcare and harm reduction services among persons who inject drugs in Seattle.

Authors:  Judith I Tsui; Claire M Miller; John D Scott; Maria A Corcorran; Julia C Dombrowski; Sara N Glick
Journal:  Drug Alcohol Depend       Date:  2018-12-26       Impact factor: 4.492

7.  Barriers to the treatment of hepatitis C. Patient, provider, and system factors.

Authors:  James A Morrill; Melissa Shrestha; Richard W Grant
Journal:  J Gen Intern Med       Date:  2005-08       Impact factor: 5.128

8.  A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care.

Authors:  Christopher E McGowan; Ali Monis; Bruce R Bacon; Josep Mallolas; Fernando L Goncales; Ioannis Goulis; Fred Poordad; Nezam Afdhal; Stefan Zeuzem; Teerha Piratvisuth; Patrick Marcellin; Michael W Fried
Journal:  Hepatology       Date:  2013-04       Impact factor: 17.425

Review 9.  Alcoholic liver disease and hepatitis C: a frequently underestimated combination.

Authors:  Sebastian Mueller; Gunda Millonig; Helmut K Seitz
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

10.  Expanding primary care capacity to treat hepatitis C virus infection through an evidence-based care model--Arizona and Utah, 2012-2014.

Authors:  Kiren Mitruka; Karla Thornton; Susanne Cusick; Christina Orme; Ann Moore; Richard A Manch; Terry Box; Christie Carroll; Deborah Holtzman; John W Ward
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-05-09       Impact factor: 17.586

View more
  2 in total

1.  Trends in fatal and nonfatal overdose by race among people who inject drugs in Baltimore, Maryland from 1998 to 2019.

Authors:  Becky L Genberg; Rachel E Gicquelais; Jacquie Astemborski; Jennifer Knight; Megan Buresh; Jing Sun; Danielle German; David L Thomas; Gregory D Kirk; Shruti H Mehta
Journal:  Drug Alcohol Depend       Date:  2021-10-30       Impact factor: 4.852

2.  Time to HCV Treatment Disfavors Patients Living with HIV/HCV Co-infection: Findings from a Large Urban Tertiary Center.

Authors:  Omar T Sims; Duong N Truong; Kaiying Wang; Pamela A Melton; Kasey Atim
Journal:  J Racial Ethn Health Disparities       Date:  2021-07-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.